Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Japan
Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Japan.
Anticancer Res. 2024 Mar;44(3):1309-1315. doi: 10.21873/anticanres.16926.
BACKGROUND/AIM: Chemotherapy and immunotherapy have been recently developed as potentially useful first-line treatments for unresectable, advanced, or recurrent esophageal cancer. We performed a retrospective study of the therapeutic effectiveness of triplet chemotherapy with docetaxel, nedaplatin, and 5-fluorouracil therapy for advanced, recurrent, and unresectable advanced esophageal cancer at our hospital and compared the regimen's results with those of current and possible future treatment options.
The study cohort comprised 101 patients who received docetaxel, nedaplatin, and 5-fluorouracil for advanced or recurrent esophageal cancer at Gunma University from May 2008 to December 2017. We retrospectively evaluated the results of this combination chemotherapy and postulated future treatment strategies.
The overall response and disease control rates, the latter including stable disease, for docetaxel, nedaplatin, and 5-fluorouracil were 33.6% and 61.4%, respectively. The median overall survival and progression-free survival were 12.26 months and 5.1 months, respectively. In patients with recurrence, the median overall and progression-free survivals were 14.97 months (449 days) and 5.1 months (152 days), respectively. No study patients developed acute kidney injury and there were no treatment-related deaths. However, leukopenia and neutropenia were frequent hematologic toxicities.
Treatment with docetaxel, nedaplatin, and 5-fluorouracil for advanced or recurrent esophageal cancer is particularly useful for recurrent cases and has the advantage of not causing severe renal dysfunction.
背景/目的：化疗和免疫疗法最近已被开发为用于不可切除的、晚期或复发性食管癌的潜在有效一线治疗方法。我们对我院接受多西紫杉醇、奈达铂和 5-氟尿嘧啶治疗的不可切除的晚期、复发性和复发性晚期食管癌的三联化疗的治疗效果进行了回顾性研究，并将该方案的结果与当前和未来可能的治疗选择进行了比较。
研究队列包括 101 名在 2008 年 5 月至 2017 年 12 月期间在群马大学接受多西紫杉醇、奈达铂和 5-氟尿嘧啶治疗的晚期或复发性食管癌患者。我们回顾性评估了该联合化疗的结果并推测了未来的治疗策略。
多西紫杉醇、奈达铂和 5-氟尿嘧啶的总体缓解率和疾病控制率（后者包括稳定疾病）分别为 33.6%和 61.4%。中位总生存期和无进展生存期分别为 12.26 个月和 5.1 个月。在复发患者中，中位总生存期和无进展生存期分别为 14.97 个月（449 天）和 5.1 个月（152 天）。没有研究患者发生急性肾损伤，也没有治疗相关死亡。然而，白细胞减少和中性粒细胞减少是常见的血液学毒性。
对于复发性食管癌患者，多西紫杉醇、奈达铂和 5-氟尿嘧啶联合治疗尤其有用，且不会导致严重肾功能障碍。
